A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

Eligible participants (N=400) with an A1c > 7.0% already prescribed a rapid-acting insulin
will be randomized to one of two groups: (1) One Drop | Premium 'On Track' (i.e., use the One
Drop | Mobile app with in-app diabetes education accredited by the American Diabetes
Association with supplemental Afrezza content and a live Certified Diabetes Educator
messaging in the app, the 'Chrome' Bluetooth-connected blood glucose meter that uploads blood
glucose values in the app, and 150 test strips per month) in combination with Afrezza
treatment (n=200) or (2) One Drop | Premium 'On Track' plus their current rapid-acting
insulin (n=200).

Inclusion Criteria:

- 18-75 years of age

- Self-reported diagnosis of T2D

- Diagnosed with diabetes for at least 12 months

- Prescribed a prandial rapid-acting insulin

- Willing to take Afrezza rapid-acting insulin for 3 months instead of current
rapid-acting insulin

- Willing to get a physician's prescription for Afrezza

- Self-reported A1c > 7.0% (later confirmed with a mail-in A1c laboratory test)

- Owns and uses an iPhone or Android phone with an operating system compatible with the
One Drop | Mobile app

- Has successfully downloaded and used a smart phone application previously

Exclusion Criteria:

- Currently pregnant or planning to become pregnant during the trial period

- Cannot read or write in English

- Currently in a diabetes education or coaching program

- Had previously used One Drop | Premium or One Drop |

- Experts coaching

- Had previously used or is currently using Afrezza

- Currently smokes (cigaretts, e-cigs, pipes, cigars, marijuana) or has smoked anytime
in the past 6 months

- Has chronic lung disease, e.g., COPD and asthma